51-61-6 Usage
Description
Dopamine, abbreviated DA, is a biosynthetic compound and neurotransmitter produced in
the body from the amino acid tyrosine by several pathways. It is synthesized in the adrenal
gland where it is a precursor to other hormones (see Epinephrine) and in several portions of
the brain, principally the substantia nigra and hypothalamus.
Originator
Dopmin,Orion Corporation,Finland
History
Dopamine is stored in vesicles
in the brain’s presynaptic nerve terminals. It is closely associated with its immediate precursor,
l-Dopa (levodopa). Casmir Funk (1884–1967) first synthesized Dopa in racemic form in 1911 and considered Dopa a vitamin. In 1913, Marcus Guggenheim, a biochemist from
Hoff man-LaRoche, isolated l-Dopa from seedlings of Vicia faba, the Windsor bean plant
native to northern Africa and southwest Asia. Guggenheim used beans from the garden of
Felix Hoff man (1868–1946), the discoverer of aspirin. Guggenheim ingested a 2.5-gram dose
of l-Dopa, resulting in nausea and vomiting; he also administered small dosages to animals
and did not observe any signifi cant effects. This led him to believe that l-Dopa was biologically
inactive. Studies commencing in 1927 reported that Dopa played a role in glucose
metabolism and aff ected arterial blood pressure. Interest in dopamine accelerated in 1938
when the German physician and pharmacologist Peter Holtz (1902–1970) and co-workers
discovered the enzyme l-Dopa decarboxylase and that it converted l-Dopa into dopamine in
humans and animals. Research over the next two decades focused on l-Dopa’s role as a precursor
to other catecholamine hormones, its vascular effects, and its role in brain chemistry.
Uses
Different sources of media describe the Uses of 51-61-6 differently. You can refer to the following data:
1. Dopamine(3-Hydroxytyramine) is used as a drug to treat several conditions. It can be injected as a solution ofdopamine hydrochloride, such as in the drug Intropin. It is used as a stimulant to the heartmuscle to treat heart conditions; it also constricts the blood vessels, increasing systolic bloodpressure and improving blood flow through the body. Dopamine is used in renal medicationsto improve kidney function and urination. Dopamine dilates blood vessels in the kidneys,increasing the blood supply and promoting the fl ushing of wastes from the body. Dopamineis used to treat psychological disorders such as schizophrenia and paranoia.
2. Adrenergic.
3. Dopamine exhibits its primary action of the cardiovascular system, kidneys, and mesentery. It is used as a temporary agent for treating hypotension and circulatory shock caused
by myocardial stroke, trauma, kidney rejection, and endogenous septicemia. The main
indication for use of this drug is shock of various origins (cardiogenic, postoperational,
infectious-toxic, anaphylactic), severe hypotension, and imminent renal insufficiency.
Definition
dopamine: A catecholamine thatis a precursor in the synthesis of noradrenalineand adrenaline. It alsofunctions as a neurotransmitter inthe brain.
Manufacturing Process
To 5 g of 3,4-dimethoxyphenylethyl amine HCl was added 20 ml of
concentrated HCl. The mixture was heated at 150°C for 2 hours. Then it wascooled to ambient temperature and decolored with a charcoal, filtered and
deluted with ethanol. The resulting crystals was isolated and re-crystallized
from acetone. The melting point of 3,4-dihydroxyphenylethylamine
hydrochloride is 174°-175°C. The free base may be prepared from this
product by adding of equivalent of NaOH or any other alkali.
Brand name
Intropin (Mayne).
Therapeutic Function
Cardiotonic
Biological Functions
Quantitatively, dopamine is the most important of the
biogenic amine neurotransmitters in the CNS.The three
major distinct dopaminergic systems in the mammalian
brain are categorized according to the lengths of the
neurons. There is a system comprising ultrashort neurons
within amacrine cells of the retina and periglomerular
cells in the olfactory bulb. Of the several
intermediate-length dopaminergic neuronal systems, the
best studied are neurons in the tuberobasal ventral hypothalamus
that innervate the median eminence and the
intermediate lobe of the pituitary. These neurons are
important in the regulation of various hypothalamohypophysial
functions, including prolactin release from the
anterior pituitary.The best-categorized of the dopamine
neuronal systems are the long projections from nuclei in
the substantia nigra and ventral tegmental areas to the
limbic cortex; other limbic structures, including the
amygdaloid complex and piriform cortex; and the neostriatum
(primarily the caudate and putamen). In
Parkinson’s disease, the primary biochemical feature is a
marked reduction in the concentration of dopamine in
this long projection system.
Several classes of drugs, notably the antipsychotics,
discussed in Chapter 34, interfere with dopaminergic
transmission. In general, dopamine appears to be an inhibitory
neurotransmitter. Five dopamine receptors
have been identified; the most important and best studied
are the D1- and D2-receptor groups.The D1-receptor,
which increases cyclic adenosine monophosphate
(cAMP) by activation of adenylyl cyclase, is located primarily
in the region of the putamen, nucleus accumbens,
and in the olfactory tubercle. The D2-receptor decreases
cAMP, blocks certain calcium channels, and
opens certain potassium channels.
General Description
Dopamine (Intropin) acts primarily on 1-and 1-adrenergic receptors, increasing systemic vascularresistance and exerting a positive inotropic effect on theheart. It must be administered by an intravenous route, becauseoral administration results in rapid metabolism byMAO and/or catechol-O-methyltransferase (COMT).
Mechanism of action
Dopamine is found in every sympathetic neuron and ganglion in the CNS. As a drug, and
in addition to stimulation of dopaminergic receptors, dopamine indirectly stimulates both
α- and β-adrenoreceptors. Dopamine also causes a release of endogenous norepinephrine.
The mechanism of action is based on the excitatory effect on β-adrenoreceptors (in low and
moderate doses), as well as on α-adrenoreceptors (in large doses). It has a positive inotropic
effect on the heart, increases blood supply, selectively widens renal and mesenteric blood
vessels, does not elevate blood pressure, and slightly increases the frequency of heartbeats.
Clinical Use
Although not strictly an adrenergic drug, dopamine is a catecholamine with properties related to the cardiovascular activities of the other agents in this chapter.
Dopamine acts on specific dopamine receptors to dilate renal vessels, increasing renal blood flow.
Dopamine also stimulates cardiac β1-receptors through both direct and indirect mechanisms. It is used to correct hemodynamic imbalances induced by conditions such
as shock, myocardial infarction, trauma, or congestive heart failure. As a catechol and primary amine, dopamine is rapidly metabolized by COMT and MAO and, similar
to dobutamine, has a short duration of action with no oral activity. It is administered as an intravenous infusion.
Synthesis
As a medicinal agent, dopamine, 2-(3,4-dihydroxyphenyl)-ethylamine
(11.3.1), is synthesized by demethylation of 2-(3,4-dimethoxyphenyl)ethylamine (19.4.3)
using hydrogen bromide [49–51].
Environmental Fate
Dopamine quinones may irreversibly alter protein function through the
formation of 5-cysteinyl-catechols on the proteins. The
formation of dopamine quinone-alpha-synuclein consequently
increases cytotoxic protofibrils and the covalent modification of
tyrosine hydroxylase by dopamine quinones. The melaninsynthetic
enzyme tyrosinase in the brain may rapidly oxidize
excess amounts of cytosolic dopamine and prevent slowly
progressive cell damage by auto-oxidation of dopamine, thus
maintaining dopamine levels.
Toxicity evaluation
High concentrations
of dopamine present inside of a cell than there are
vesicles to store it in, oxidative stress can occur and cause damage
or death to the cell. It is thought that dopamine overload causes
biochemical damage to cellular mitochondria, that provide the
cell with all of the energy it requires to function, resulting in
death of the cell. Catecholamines produced circulatory changes
that reversed propofol anesthesia in animal models.
Check Digit Verification of cas no
The CAS Registry Mumber 51-61-6 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 1 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 51-61:
(4*5)+(3*1)+(2*6)+(1*1)=36
36 % 10 = 6
So 51-61-6 is a valid CAS Registry Number.
InChI:InChI=1/C8H11NO2.ClH/c9-4-3-6-1-2-7(10)8(11)5-6;/h1-2,5,10-11H,3-4,9H2;1H
51-61-6Relevant articles and documents
La Rocca,Mc Clure
, p. 584 (1963)
Optimisation of nutritional requirements for dopamine synthesis by calcium alginate-entrapped mutant strain of Aspergillus oryzae EMS-6
Ali, Sikander,Nawaz, Wajeeha
, p. 281 - 288 (2017)
The optimisation of nutritional requirements for dopamine (DA) synthesis by calcium alginate-entrapped mutant variant of Aspergillus oryzae EMS-6 using submerged fermentation technique was investigated. A total of 13 strains were isolated from soil. Isolate I-2 was selected as a better producer of DA and improved by exposing with ethyl methylsulphonate (EMS). EMS-6 was selected as it exhibited 43?μg/mL DA activity. The mutant variable was further treated with low levels of l-cysteine HCl to make it resistant against diversion and environmental stress. The conidiospores of mutant variant were entrapped in calcium alginate beads for stable product formation. EMS-6 gave maximum DA activity (124?μg/mL) when supplemented with 0.1% peptone and 0.2% sucrose, under optimised parameters viz. pH 3, temperature of 55?°C and incubation time of 70?min. The study involves the high profile of DA activity and is needed, as DA is capable to control numerous neurogenic disorders.
Photoactivatable Dopamine and Sulpiride to Explore the Function of Dopaminergic Neurons and Circuits
Asad, Naeem,Condon, Alec F.,Dore, Timothy M.,Gore, Sangram,Hampton, Shahienaz E.,Mclain, Duncan E.,Vijay, Sauparnika,Williams, John T.
, p. 939 - 951 (2020/04/09)
Kinetic analysis of dopamine receptor activation and inactivation and the study of dopamine-dependent signaling requires precise simulation of the presynaptic release of the neurotransmitter dopamine and tight temporal control over the release of dopamine receptor antagonists. The 8-cyano-7-hydroxyquinolinyl (CyHQ) photoremovable protecting group was conjugated to dopamine and the dopamine receptor antagonist sulpiride to generate "caged" versions of these neuromodulators (CyHQ-O-DA and CyHQ-sulpiride, respectively) that could release their payloads with 365 or 405 nm light or through 2-photon excitation (2PE) at 740 nm. These compounds are stable under physiological conditions in the dark, yet photolyze rapidly and cleanly to yield dopamine or sulpiride and the caging remnant CyHQ-OH. CyHQ-O-DA mediated the light activation of dopamine-1 (D1) receptors on the breast cancer cell line MDA-MB-231 in culture. In mouse brain slice from the substantia nigra pars compacta, localized flash photolysis of CyHQ-O-DA accurately mimicked the natural presynaptic release of dopamine and activation of dopamine-2 (D2) receptors, causing a robust, concentration-dependent, and repeatable G protein-coupled inwardly rectifying potassium channel-mediated outward current in whole-cell voltage clamp recordings that was amplified by cocaine and blocked by sulpiride. Photolysis of CyHQ-sulpiride rapidly blocked synaptic activity, enabling measurement of the unbinding rates of dopamine and quinpirole, a D2 receptor agonist. These tools will enable more detailed study of dopamine receptors, their interactions with other GPCRs, and the physiology of dopamine signaling in the brain.
The Study of Stability of Proline-Containing Derivatives of Dopamine and Serotonin in the Biological Media in Vitro Experiments
Andreeva, L. A.,Myasoedov, N. F.,Nagaev, I. Yu.,Shevchenko, K. V.,Shevchenko, V. P.
, p. 150 - 158 (2020/05/28)
Abstract—: The peptides Boc-Gly-Pro-DP, Z-Gly-Pro-DP, LA-Gly-Pro-DP, Boc-Gly-Pro-Srt, Z-Gly-Pro-Srt have been synthesized for the first time. The study of their stability in the presence of leucine aminopeptidase, carboxypeptidase Y, carboxypeptidase B, and proline endopeptidase (PEP) has shown that the synthesized peptides are stable in the presence of aminopeptidases and carboxypeptidases. In the presence of PEP, dopamine (DP) and serotonin (Srt) have been cleaved from these substances. Thus, the originally synthesized proline derivatives of Srt and DP may be considered as the resources, from which Srt and DP can be gradually released. This creates the possibility of a prolonged action of these biologically active compounds on cells and, consequently, on the whole body.
